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Environment as therapy: neuroscience for intellectual disability 
and dementia
Gabriele Sansevero and Alessandro Sale
Reversing conditions characterized by intellectual 
disability or dementia is one major challenge in basic and 
applied Neuroscience. This varied group of pathologies 
is highly heterogeneous and comprises, among others, 
neurodevelopmental disorders such as autism, Rett 
syndrome, and Down syndrome, and age-dependent 
neurodegenerative diseases such as Alzheimer’s disease 
(AD). Despite the heterogeneous etiology, recent 
research has underscored common cellular and molecular 
mechanisms underlying key neuropathological signs 
associated with these disorders, with emerging hub roles 
for GABAergic overinhibition, altered mGluR signaling, 
alterations in key neurotrophic factors, and dysfunctions 
in the metabolism of β-amyloid protein. The increased 
knowledge of molecular details has greatly expanded the 
attempts aimed at a pharmacological correction, with a 
growing number of studies reporting a marked phenotypic 
rescue in various transgenic mouse models of these 
disorders. 
One paradigmatic case is that of Down syndrome 
(DS), a condition due to the presence of an extra copy 
of the human chromosome 21 and representing the most 
common genetic cause of intellectual disability. People 
with DS exhibit a complex phenotype characterized by 
a wide range of functional dysfunctions, encompassing 
attention and sensory deficits and moderate to severe 
mental retardation [1]. Moreover, subjects with DS 
invariantly show a precocious onset of AD, due to the 
triplication of the β-amyloid precursor protein gene, which 
is located on chromosome 21 [1]. This complex phenotype 
is faithfully recapitulated by the Ts65Dn mouse line, the 
most widely investigated animal model of DS, bearing 
a triplication for over half of the human chromosome 
21 mouse gene orthologs. Recent attempts to ameliorate 
the phenotype of Ts65Dn mice have led to potentially 
interesting treatments as various as estrogen delivery, 
administration of GABA receptor or NMDA receptor 
antagonists, fluoxetine, lithium, acetylcholinesterase 
inhibitors, beta-adrenergic receptor agonists, bumetanide, 
and Epigallocatechin-3-gallate [2]. Despite great efforts 
devoted to develop suitable therapeutic approaches, 
however, there is still no effective cure for DS, and some 
of the proposed pharmacological approaches, such as the 
direct modulation of GABA receptors, raise concerns 
on their potential for clinical application, given that in 
many occasions the proposed drugs have either been not 
approved by the FDA or have an undesired proconvulsant 
action. 
Figure 1: Impact of environmental enrichment in Ts65Dn mice.
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While awaiting for the good cocktail of pharma, 
mother Nature can go to Nurture’s school to get some 
help, or hints, or a combination of the two. In the last 
decades environmental enrichment (EE), a combination 
of sensory, motor and cognitive stimulation, has emerged 
as a valuable tool capable to stimulate cerebral plasticity 
both during the development and in the adulthood, with a 
totally non-invasive approach that renders this paradigm 
particularly interesting in terms of application to humans. 
EE exerts powerful effects on neural connectivity, 
enhancing hippocampal synaptic plasticity and learning 
and memory abilities, and positively interacting with 
various factors involved in neural plasticity, including 
NMDA receptors, inhibitory circuitry, intracellular 
kinases, neuromodulators, hippocampal neurogenesis, 
transcriptional and epigenetic factors, and neurotrophins 
[3]. Focusing on DS, we recently demonstrated that 
exposure to EE in adult Ts65Dn mice normalizes the 
intracerebral inhibitory-excitatory balance and restores 
hippocampal synaptic plasticity, learning abilities and 
visual functions [4] (see Figure). Similar effects were also 
reported in younger animals reared under EE conditions 
from birth, which received, compared to standard-reared 
age-matched controls, enhanced levels of maternal care, 
one of the most important sources of sensory experience 
during the early postnatal period [5]. The sooner, the 
better. Accordingly, early interventions based on EE have 
been also shown to correct brain development in other 
developmental disorders, such as Fragile X syndrome, 
Rett syndrome, and visual system deficits [3].
Strikingly, the beneficial effects of EE are not 
restricted to early life stages. Long-term exposure to 
EE prevents, in the hippocampus of aged Ts65Dn mice, 
the age-dependent increase of low molecular weight Aβ 
oligomer isoforms, the most dangerous molecular species 
triggering synapse failure and memory impairment in AD-
like dementia [6]. Aged enriched Ts65Dn mice, compared 
to controls reared in standard conditions, show learning 
and memory performances that do not differ from those 
achieved by wild-type, euploid, controls [6] (see Figure). 
Analogously, EE has been also found to either prevent or 
reverse many neuropathological and behavioral signs of 
AD in several transgenic mouse models of this pathology 
[3]. 
Normalization of development, reversion of adult 
dysfunctions, prevention of AD-like neuropathology 
in elderly subjects: these remarkable effects should 
not be held as a miracle, as they rely on the EE ability 
to impact at several molecular substrate levels in the 
brain, including stimulation of maturational processes by 
enhancing the activation of growth factors, reopening of 
plasticity windows through reduced intracortical inhibition 
and promoting plastic structural and functional changes 
through neurotrophin increments, which could in turn 
increase the expression of genes specifically involved in 
brain plasticity.
These studies have profound consequences for 
humans. The development of intervention protocols aimed 
at ensuring proper levels of environmental stimulation 
and at maintaining a healthy and active lifestyle has 
been effectively encouraged by basic research on EE. 
A recent study in humans showed that an early multi-
sensory intervention, based on infant body massage and 
directly inspired by research on maternal stimulation in 
rodents, promotes a significantly higher visual acuity in 
DS children at 6 months of age, leading to an accelerated 
development which persists up to at least 12 months [7]. 
Strong correlative and epidemiological evidence shows 
that a higher level and variety of mental and physical 
activity is associated with lower cognitive decline and 
reduced risk for dementia [3]. Most informatively, 
multidomain interventions based on enhanced exercise 
and cognitive training have been proved highly effective 
in improving cognitive performances not only in aged, 
healthy people, but even in Mild Cognitive Impairment 
subjects at high risk to develop dementia [8].
Future treatments in this field should combine the 
administration of new pharmacological therapeutics with 
an endogenous pharmacotherapy based on the intrinsic 
capability of environmental stimulation to enhance the 
spontaneous reparative potential held by the brain.
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